MTOR and hepatocellular carcinoma: Treatment with Rosuvastatin and mTOR inhibitor Vistusertib was reported to restore NKT expansion suppressed hepatic cholesterol biosynthesis and prevented obesogenic diet-promoted HCC development [144].